Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311882 | 1.00 | TLR2 (0.54) | TLR2KMT2ASIRT2SIRT1SIRT3 | |
| SCHEMBL13319576 | 0.94 | TLR2 (0.49) | TLR2KMT2ATPSAB1 | |
| SCHEMBL13311876 | 0.89 | TLR2 (0.61) | TLR2 | |
| SCHEMBL12019008 | 0.86 | TLR2 (0.49) | TLR2KMT2ATPSAB1 | |
| SCHEMBL27407607 | 0.86 | TLR2 (0.57) | TLR2 | |
| SCHEMBL16592017 | 0.85 | KMT2A (0.58) | TLR2KMT2ATPSAB1 | |
| SCHEMBL13938802 | 0.85 | KMT2A (0.59) | TLR2KMT2ATPSAB1 | |
| SCHEMBL17751581 | 0.85 | TLR2 (0.57) | TLR2KMT2ASIRT2SIRT1SIRT3 | |
| SCHEMBL14374823 | 0.85 | MMP2 (0.54) | TLR2 | |
| SCHEMBL12040119 | 0.84 | MDM2 (0.54) | TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160210-A1 | GUANIDINIUM DELIVERY CARRIERS | NITTO DENKO CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20070078094-A1 | Guanidinium delivery carriers | NITTO DENKO CORPORATION (JP) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160210-A1 | GUANIDINIUM DELIVERY CARRIERS | SLC2A9, SLC29A2, SLC2A4 | TLR2 1760/4885KMT2A 4242/4885SIRT2 2918/4885 |
| US-20070078094-A1 | Guanidinium delivery carriers | SLC2A9, SLC29A2, SLC2A4 | TLR2 1760/4885KMT2A 4242/4885SIRT2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.